402 related articles for article (PubMed ID: 33713047)
21. RELL1, a novel oncogene, accelerates tumor progression and regulates immune infiltrates in glioma.
Jin X; Xie H; Liu X; Shen Q; Wang Z; Hao H; Gu Y
Int Immunopharmacol; 2020 Oct; 87():106707. PubMed ID: 32683297
[TBL] [Abstract][Full Text] [Related]
22. Integrative Analysis of Neuregulin Family Members-Related Tumor Microenvironment for Predicting the Prognosis in Gliomas.
Zhao WJ; Ou GY; Lin WW
Front Immunol; 2021; 12():682415. PubMed ID: 34054873
[TBL] [Abstract][Full Text] [Related]
23. An Immune-Related lncRNA Signature to Predict Survival In Glioma Patients.
Xia P; Li Q; Wu G; Huang Y
Cell Mol Neurobiol; 2021 Mar; 41(2):365-375. PubMed ID: 32410107
[TBL] [Abstract][Full Text] [Related]
24. Next-generation sequencing identifies HOXA6 as a novel oncogenic gene in low grade glioma.
Xiulin J; Wang C; Guo J; Wang C; Pan C; Nie Z
Aging (Albany NY); 2022 Mar; 14(6):2819-2854. PubMed ID: 35349479
[TBL] [Abstract][Full Text] [Related]
25. Identification and validation of anoikis-related genes to clarify the prognosis and immune mechanisms of patients with low-grade glioma.
Wang J; Liu Y; Qian M; Xu W; Chen J; Deng Y; Luo R; Chen J; Jia W; Liu L; Tian C
Biochem Biophys Res Commun; 2024 Jun; 711():149894. PubMed ID: 38603834
[TBL] [Abstract][Full Text] [Related]
26. Grade II/III Glioma Microenvironment Mining and Its Prognostic Merit.
Chen J; Hou C; Wang P; Yang Y; Zhou D
World Neurosurg; 2019 Dec; 132():e76-e88. PubMed ID: 31518750
[TBL] [Abstract][Full Text] [Related]
27. Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.
Liu Z; Cheng X; Pang B; Wang S; Liu B; Cao C; Qian R; Liang W; Zhu Y; Li P; Gao Y
Int Immunopharmacol; 2022 Mar; 104():108399. PubMed ID: 35008004
[TBL] [Abstract][Full Text] [Related]
28. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
29. CKAP2L Knockdown Exerts Antitumor Effects by Increasing miR-4496 in Glioblastoma Cell Lines.
Li YF; Tsai WC; Chou CH; Huang LC; Huang SM; Hueng DY; Tsai CK
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33375517
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation-regulated YTHDF2 correlates with cell migration and immune cell infiltration in glioma.
Jiang X; Chen X; Huang X; Wang C; Wang C; Pan C; Cho WC; Nie Z; Pu J; Wang W
Aging (Albany NY); 2022 Jun; 14(19):7774-7793. PubMed ID: 35661004
[TBL] [Abstract][Full Text] [Related]
31. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
32. Upregulated Tripartite Motif 47 Could Facilitate Glioma Cell Proliferation and Metastasis as a Tumorigenesis Promoter.
Ji B; Liu L; Guo Y; Ming F; Jiang J; Li F; Zhao G; Wen J; Li N
Comput Math Methods Med; 2021; 2021():5594973. PubMed ID: 33833824
[TBL] [Abstract][Full Text] [Related]
33. Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma.
Wang Z; Wang Z; Zhang C; Liu X; Li G; Liu S; Sun L; Liang J; Hu H; Liu Y; Zhang W; Jiang T
Cancer Sci; 2018 Sep; 109(9):2697-2705. PubMed ID: 30027617
[TBL] [Abstract][Full Text] [Related]
34. Interferon regulatory factor transcript levels correlate with clinical outcomes in human glioma.
Lei J; Zhou MH; Zhang FC; Wu K; Liu SW; Niu HQ
Aging (Albany NY); 2021 Apr; 13(8):12086-12098. PubMed ID: 33902005
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive exploration of tumor mutational burden and immune infiltration in diffuse glioma.
Kang K; Xie F; Wu Y; Wang Z; Wang L; Long J; Lian X; Zhang F
Int Immunopharmacol; 2021 Jul; 96():107610. PubMed ID: 33848908
[TBL] [Abstract][Full Text] [Related]
36. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
37. RAB38 confers a poor prognosis, associated with malignant progression and subtype preference in glioma.
Wang H; Jiang C
Oncol Rep; 2013 Nov; 30(5):2350-6. PubMed ID: 24026199
[TBL] [Abstract][Full Text] [Related]
38. IL-6 significantly correlated with the prognosis in low-grade glioma and the mediating effect of immune microenvironment.
Yang SD; Chen MZ; Yang DF; Hu SB; Zheng DD
Medicine (Baltimore); 2024 May; 103(19):e38091. PubMed ID: 38728467
[TBL] [Abstract][Full Text] [Related]
39. Six Immune Associated Genes Construct Prognostic Model Evaluate Low-Grade Glioma.
Tan YQ; Li YT; Yan TF; Xu Y; Liu BH; Yang JA; Yang X; Chen QX; Zhang HB
Front Immunol; 2020; 11():606164. PubMed ID: 33408717
[TBL] [Abstract][Full Text] [Related]
40. Transcriptional expression of ZICs as an independent indicator of survival in gliomas.
Han Z; Jia J; Lv Y; Wang R; Cao K
Sci Rep; 2021 Sep; 11(1):17532. PubMed ID: 34475426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]